150 related articles for article (PubMed ID: 2880862)
41. Effects of transdermal 17 beta-estradiol treatment and naloxone infusion on gonadotropin response to gonadotropin-releasing hormone in postmenopausal women.
Cagnacci A; Melis GB; Paoletti AM; Soldani R; Fioretti P
J Clin Endocrinol Metab; 1990 Feb; 70(2):365-70. PubMed ID: 2105330
[TBL] [Abstract][Full Text] [Related]
42. Endogenous opiates modulate pulsatile luteinizing hormone release in humans.
Ropert JF; Quigley ME; Yen SS
J Clin Endocrinol Metab; 1981 Mar; 52(3):583-5. PubMed ID: 6780598
[TBL] [Abstract][Full Text] [Related]
43. Chronic naltrexone treatment induces desensitization of the luteinizing hormone pulse generator for opioid blockade in hyperprolactinemic patients.
de Wit W; Schoute E; Schoemaker J
J Clin Endocrinol Metab; 1995 May; 80(5):1739-42. PubMed ID: 7745028
[TBL] [Abstract][Full Text] [Related]
44. Elevation of plasma immunoreactive luteinizing hormone releasing hormone in hyperprolactinemic-amenorrheic women on bromocriptine therapy.
Elkind-Hirsch KE; Platia MP; Schiff I
J Reprod Med; 1987 Jan; 32(1):5-9. PubMed ID: 3550065
[TBL] [Abstract][Full Text] [Related]
45. Effects of acute hyperprolactinemia on LH pulsatile secretion in hypogonadal and early follicular phase women.
Rossmanith WG; Mortola JF; Yen SS
Life Sci; 1988; 43(3):247-53. PubMed ID: 3398697
[TBL] [Abstract][Full Text] [Related]
46. Neonatal organization of the brain opioid systems controlling prolactin and luteinizing hormone secretion.
Limonta P; Dondi D; Maggi R; Martini L; Piva F
Endocrinology; 1989 Feb; 124(2):681-6. PubMed ID: 2912695
[TBL] [Abstract][Full Text] [Related]
47. Hormone ontogeny in the ovine fetus. XVIII. The effect of an opioid antagonist on luteinizing hormone secretion.
Cuttler L; Egli CA; Styne DM; Kaplan SL; Grumbach MM
Endocrinology; 1985 May; 116(5):1997-2002. PubMed ID: 3987627
[TBL] [Abstract][Full Text] [Related]
48. Opioid control of luteinizing hormone secretion in humans.
Genazzani AR; Petraglia F
J Steroid Biochem; 1989 Oct; 33(4B):751-5. PubMed ID: 2689783
[TBL] [Abstract][Full Text] [Related]
49. Endogenous opioid peptides modulate the effect of corticotropin-releasing factor on gonadotropin release in the primate.
Gindoff PR; Ferin M
Endocrinology; 1987 Sep; 121(3):837-42. PubMed ID: 3113919
[TBL] [Abstract][Full Text] [Related]
50. Responses of growth hormone to metoclopramide in normal women and amenorrheic women with or without hyperprolactinemia.
Seki K; Kato K
Endocrinol Jpn; 1986 Oct; 33(5):721-5. PubMed ID: 3830074
[TBL] [Abstract][Full Text] [Related]
51. Pituitary autonomy in hyperprolactinemic secondary amenorrhea: results of hypothalamic-pituitary testing.
Healy DL; Pepperell RJ; Stockdale J; Bremner WJ; Burger HG
J Clin Endocrinol Metab; 1977 May; 44(5):809-19. PubMed ID: 404308
[TBL] [Abstract][Full Text] [Related]
52. Chronic bromocriptine administration restores luteinizing hormone response to naloxone in postmenopausal women.
Melis GB; Cagnacci A; Gambacciani M; Paoletti AM; Caffi T; Fioretti P
Neuroendocrinology; 1988 Feb; 47(2):159-63. PubMed ID: 2830551
[TBL] [Abstract][Full Text] [Related]
53. [Variations of the plasma levels of gonadotrophins (FSH and LH) and of its response to stimulation with gonadotrophin releasing hormone (GnRH) with different plasma levels of prolactin (PRL) in women with the syndrome of galactorrhea-amenorrhea (author's transl)].
Salmerón de Diego J; Alonso RodrÃguez C; Santos Reyero M; Salazar Orlando A; Palacios Mateos JM
Med Clin (Barc); 1981 Feb; 76(4):164-8. PubMed ID: 6782394
[TBL] [Abstract][Full Text] [Related]
54. Restoration of luteinizing hormone response to naloxone in postmenopausal women by chronic administration of the antidopaminergic drug veralipride.
Melis GB; Cagnacci A; Gambacciani M; Paoletti AM; Moggi L; Fioretti P
J Clin Endocrinol Metab; 1988 May; 66(5):964-7. PubMed ID: 2834413
[TBL] [Abstract][Full Text] [Related]
55. Hypoglycemia-induced inhibition of luteinizing hormone secretion in the rhesus monkey is not mediated by endogenous opioid peptides.
Heisler LE; Pallotta CM; Reid RL; Van Vugt DA
J Clin Endocrinol Metab; 1993 May; 76(5):1280-5. PubMed ID: 8388404
[TBL] [Abstract][Full Text] [Related]
56. Gonadectomy influences the inhibitory effect of the endogenous opiate system on pulsatile gonadotropin secretion.
Masotto C; Negro-Vilar A
Endocrinology; 1988 Aug; 123(2):747-52. PubMed ID: 2840268
[TBL] [Abstract][Full Text] [Related]
57. Gonadotropin and prolactin pulsations in hyperprolactinemic women before and during bromocriptine therapy.
Klibanski A; Beitins IZ; Merriam GR; McArthur JW; Zervas NT; Ridgway EC
J Clin Endocrinol Metab; 1984 Jun; 58(6):1141-7. PubMed ID: 6427260
[TBL] [Abstract][Full Text] [Related]
58. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia.
Kishimoto T; Watanabe K; Shimada N; Makita K; Yagi G; Kashima H
J Clin Psychiatry; 2008 Mar; 69(3):385-91. PubMed ID: 18278991
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of dopaminergic tone in hyperprolactinemia. III. Thyroid-stimulating hormone response to metoclopramide in differential diagnosis and postoperative follow-up of prolactinoma patients.
De Marinis L; Mancini A; Minnielli S; Masala R; Anile C; Maira G; Barbarino A
Metabolism; 1985 Oct; 34(10):917-22. PubMed ID: 4046835
[TBL] [Abstract][Full Text] [Related]
60. Bone density in amenorrheic women with and without hyperprolactinemia.
Schlechte JA; Sherman B; Martin R
J Clin Endocrinol Metab; 1983 Jun; 56(6):1120-3. PubMed ID: 6404918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
